These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34346472)

  • 1. Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles.
    Hymel D; Tsuji K; Grant RA; Chingle RM; Kunciw DL; Yaffe MB; Burke TR
    Org Biomol Chem; 2021 Sep; 19(36):7843-7854. PubMed ID: 34346472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.
    Hymel D; Grant RA; Tsuji K; Yaffe MB; Burke TR
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3202-3205. PubMed ID: 30174151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.
    Murugan RN; Park JE; Lim D; Ahn M; Cheong C; Kwon T; Nam KY; Choi SH; Kim BY; Yoon DY; Yaffe MB; Yu DY; Lee KS; Bang JK
    Bioorg Med Chem; 2013 May; 21(9):2623-34. PubMed ID: 23498919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
    Zhao XZ; Hymel D; Burke TR
    Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position.
    Qian W; Park JE; Liu F; Lee KS; Burke TR
    Bioorg Med Chem; 2013 Jul; 21(14):3996-4003. PubMed ID: 22743087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.
    Liu F; Park JE; Qian WJ; Lim D; Scharow A; Berg T; Yaffe MB; Lee KS; Burke TR
    ACS Chem Biol; 2012 May; 7(5):805-10. PubMed ID: 22292814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.
    Qian WJ; Park JE; Lim D; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Chem Biol; 2013 Oct; 20(10):1255-64. PubMed ID: 24120332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
    Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
    Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
    Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
    Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
    J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high Plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in HeLa cells.
    Qian WJ; Park JE; Lim D; Lai CC; Kelley JA; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Biopolymers; 2014 Nov; 102(6):444-55. PubMed ID: 25283071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific inhibition of an anticancer target, polo-like kinase 1, by allosterically dismantling its mechanism of substrate recognition.
    Park JE; Kirsch K; Lee H; Oliva P; Ahn JI; Ravishankar H; Zeng Y; Fox SD; Kirby SA; Badhwar P; Andresson T; Jacobson KA; Lee KS
    Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2305037120. PubMed ID: 37603740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).
    Qian WJ; Park JE; Lee KS; Burke TR
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7306-8. PubMed ID: 23159568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
    Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T
    J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mining Polo-Box domain of Polo-like kinase 1 as a new therapeutic target for cancer].
    Fu Z; Su M; Liu X; Chen Y
    Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2298-2312. PubMed ID: 33244925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
    Yan F; Liu G; Chen T; Fu X; Niu MM
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.
    Murugan RN; Ahn M; Lee WC; Kim HY; Song JH; Cheong C; Hwang E; Seo JH; Shin SY; Choi SH; Park JE; Bang JK
    PLoS One; 2013; 8(11):e80043. PubMed ID: 24223211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
    Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.